UC Davis Year 2 Student · NPB Major
This report provides a structured framework for evaluating whether to pursue both a PharmD pathway and the MEPN (Master's Entry Program in Nursing) pathway simultaneously. Unlike the MD, MEPN requires no MCAT, but it does require distinct prerequisites, clinical experience, and a separate application process.
Before any timeline or course plan is relevant, you need to answer one question honestly:
"If you were guaranteed admission to a solid, respected PharmD program tomorrow — not UCSF, just a good program — would you still feel a genuine pull toward becoming a registered nurse and then an advanced practice nurse?"
Your honest answer determines everything that follows. The dual-path framework only makes sense if the answer is genuinely yes.
Neither path is objectively better. They represent meaningfully different clinical roles, training timelines, and career trajectories. The question is which life you want.
Do not pursue MEPN. It adds prerequisite courses, clinical hours, a separate application, and admission risk with no strategic benefit to the pharmacy path. Stop at Section 2 and execute the pharmacy plan fully.
A structured dual-path is viable. MEPN prerequisites overlap substantially with PharmD prerequisites under Option A. Continue to Section 3 for the full dual-path framework.
Option A (NPB + selective pharmaceutical chemistry electives) is not just compatible with MEPN — it is the ideal preparation for it. The MEPN does not require a separate high-stakes exam like the MCAT. The admissions leverage comes entirely from GPA, prerequisites, and clinical experience.
Every required MEPN prerequisite is already part of Option A or can be added as a low-risk elective. NPB 101 (Physiology), EXB 106/106L (Anatomy), and MMG 102 (Microbiology) are required by both PharmD and MEPN programs. The overlap is near-total — unlike the MD path, which requires MCAT prep as a separate sustained effort.
MEPN Prerequisite Alignment with Option A
| Prerequisite | Option A Course | UC Davis MEPN | UCI MEPN | Samuel Merritt |
|---|---|---|---|---|
| Human Physiology w/ Lab | NPB 101 + NPB 101L | REQUIRED | REQUIRED | REQUIRED |
| Human Anatomy w/ Lab | EXB 106 + EXB 106L | REQUIRED | REQUIRED | REQUIRED |
| Microbiology w/ Lab | MMG 102 + lab | REQUIRED | REQUIRED | REQUIRED |
| General Chemistry | CHE 002A/B/C | REQUIRED | REQUIRED | REQUIRED |
| Organic Chemistry | CHE 8AB or CHE 118A/B | REQUIRED | REQUIRED | REQUIRED |
| Statistics | STA 13 or STA 100 | REQUIRED | REQUIRED | REQUIRED |
| Nutrition | NUT 10 or NUT 11 | REQUIRED | Recommended | Recommended |
| Psychology | PSC 1 | REQUIRED | REQUIRED | REQUIRED |
| Oral Communication | CMN 1, CMN 5, or CMN 120 | REQUIRED | REQUIRED | REQUIRED |
| Biochemistry | BIS 103 | Not required | Recommended | Recommended |
| Lifespan Development | HDE 100A/B/C | REQUIRED | REQUIRED | REQUIRED |
UCSF School of Nursing began formal reassessment in Fall 2025 and has not announced a timeline for resumption. For a student applying in 2027–2028, UCSF MEPN should be treated as an uncertain target until an official reopening is announced. USC entry MSN is no longer accepting new cohorts as of 2024–2025 and should be removed from your target list. Monitor: nursing.ucsf.edu/admissions
Three Additional Prerequisites Option A Does Not Fully Cover
None are GPA risks; all are manageable in light quarters:
| Missing Prerequisite | UC Davis Course | When to Take |
|---|---|---|
| Statistics | STA 13 or STA 100 | Summer 2026 or as a light-quarter filler. Low difficulty. Does not compete with PharmD GPA. |
| Nutrition | NUT 10 or NUT 11 | Any quarter with available units (2–3 units). Highly compatible with NPB coursework. |
| Lifespan Human Development | HDE 100A/B/C (one required) | Any quarter with available units. Non-science GPA booster. |
| Oral Communication | CMN 1, CMN 5, or CMN 120 | Usually completed in Year 1–2. Confirm already completed; if not, add to any light quarter. |
Do not frame this as: "If I fail top PharmD programmes, I'll try nursing."
Frame this as: "If nursing genuinely interests me as a clinical path, I will structure my timeline now so both applications are strong — and I will make a fully informed decision in Spring 2028 with both pharmacy results and nursing admissions outcomes in hand."
Deadline: Nov 1 (NursingCAS). Home institution advantage. 5-year rule for Anatomy/Physiology. Strong fit for NPB background.
Deadline: Oct–Dec (NursingCAS + UCI Graduate Application). Requires both application systems.
Rolling admissions. Strong Bay Area clinical network. More accessible than UC programmes. Good safety option.
Reassessment underway Fall 2025. Do not include in plans until officially reopened. Monitor nursing.ucsf.edu.
Remove from target list. No longer accepting new cohorts as of 2024–2025.
Competitive Applicant Profile for UC Davis and UCI MEPN
| Component | Competitive Target |
|---|---|
| Overall GPA | 3.5–3.7+ (minimum 3.0; UC Davis average admitted class ~3.5–3.6) |
| Science Prerequisite GPA | 3.5+ (Anatomy, Physiology, Chemistry, Microbiology labs; calculated separately at UC Davis) |
| Healthcare clinical hours | 150–300 hours minimum; mix of direct patient care (hospital/clinic) and healthcare volunteering |
| Nursing-specific exposure | At minimum: shadowing of RN or NP, ideally in 2+ settings (acute care + primary care or specialty) |
| Letters of recommendation | 2–3 letters; at least one from a registered nurse or nurse practitioner; one from science faculty (Franz lab ideal) |
| Personal statement | Must articulate specific nursing identity — why nurse, not just "healthcare." Patient care experiences must anchor the narrative. |
| GRE | Not required at UC Davis or UCI MEPN. No exam prep burden. |
Most MEPN applicants have solid prerequisite GPAs but no research experience. An NPB student with 1–2 years in a named faculty research lab (organic synthesis, medicinal chemistry, NMR, HPLC, mRNA delivery chemistry) stands out in a pool where research experience is rare.
Important caveat: MEPN committees weight clinical readiness, patient care identity, and service orientation more heavily than research. Franz lab experience is a meaningful differentiator — not a primary driver. Strong nursing clinical hours and a patient-centered personal statement remain the core of a competitive application.
Prof. Franz's role as Associate Dean for Undergraduate Education also makes her an institutional reference with name recognition at UC Davis — a meaningful advantage for the home institution application.
Question Set A: Career Motivation
Question Set B: Practical Readiness
Question Set C: Risk Tolerance
This is the predictable outcome of treating MEPN as a consolation application. The antidote is the proactive framing in Section 3: decide early, build the nursing clinical portfolio in parallel, and draft a nursing personal statement grounded in actual patient care experiences.
The most common mistake is assuming that pharmacy technician hours satisfy MEPN clinical hour requirements. They do not. MEPN programmes want evidence of direct patient care — hospital volunteering, CNA work, clinical shadowing of RNs in acute care settings. Pharmacy experience demonstrates healthcare exposure but not the bedside care orientation that nursing school screens for.
If you pursue the dual path correctly, you will arrive in Spring 2028 with PharmD and MEPN admissions decisions arriving in roughly the same window. Work through the hypothetical scenarios now so the decision is not made under time pressure.
| PharmD Outcome | MEPN Outcome | Recommended Decision Logic |
|---|---|---|
| Best Case Admitted to target PharmD |
Admitted to MEPN | Choose based on which clinical role genuinely fits. This is the decision you prepared for. |
| Strong Admitted to target PharmD |
Not admitted to MEPN | Accept PharmD. Strong outcome. MEPN reapplication possible after PharmD if interest persists, or NP pathway via PharmD is viable. |
| Viable Admitted to lower-tier PharmD only |
Admitted to MEPN | Genuine decision point. Evaluate programme quality and career alignment. Both are viable professional degrees. |
| Viable Admitted to lower-tier PharmD only |
Not admitted to MEPN | Accept best PharmD if solid programme. Reapply to MEPN with stronger clinical hours if nursing interest remains. |
| Viable Not admitted to PharmD |
Admitted to MEPN | Accept MEPN. This is not a consolation — it is a professional doctorate pathway with significantly expanded prescribing and practice authority at the NP/DNP level in California under AB 890. |
| Gap Year Not admitted to PharmD |
Not admitted to MEPN | Gap year for simultaneous reapplication. Strengthen clinical hours, GPA if possible, and personal statements. Both paths remain viable with stronger profiles. |
In California, AB 890 (signed 2020, implementation began 2023) created expanded autonomy pathways for qualified NPs and DNP-prepared nurses to diagnose, prescribe, and manage patients under defined regulatory requirements — including a supervised transition period and board approval.
The PharmD + NP/DNP combination — achieved by completing MEPN then pursuing a DNP — creates a uniquely powerful dual credential in areas like oncology, palliative care, and clinical pharmacology that relatively few practitioners hold.
| Is the dual path possible? | Yes. MEPN prerequisites overlap almost entirely with Option A. No separate exam required. |
| Is it advisable? | Only if nursing is a genuine clinical calling, not insurance against pharmacy rejection. |
| What does MEPN require beyond PharmD? | Direct patient care clinical hours (nursing-specific), a separate nursing personal statement, Statistics, Nutrition, HDE/CMN courses, and an RN/NP letter of recommendation. |
| Best application timing? | PharmCAS by early July 2027. NursingCAS by November 1, 2027. The stagger makes simultaneous applications manageable. |
| When does prep start? | Clinical nursing volunteer hours begin Spring 2026. Missing prerequisites (Stats, Nutrition, HDE) added in light quarters 2026–2027. |
| Decision point? | Spring 2028, when both PharmD and MEPN decisions arrive. Full information, no reactive pressure. |
| Does UCSF MEPN factor in? | Not currently. UCSF MEPN is paused as of February 2026. UC Davis and UCI are the primary targets. |
| Does Franz lab help? | Yes — significantly. Research experience is rare in MEPN applicant pools and Prof. Franz's profile is an institutional advantage at UC Davis specifically. |
Immediate Action Items — This Week (February 2026)
The nursing path requires no extra exam. It requires extra clinical identity.
You can build that identity starting this week by walking into a hospital as a volunteer and learning what nurses actually do. No MCAT prep course needed. Just time, presence, and honest self-reflection about whether that is the clinical life you want.
This section provides context on what PharmD residency actually costs, what residents earn, whether not finding a job after residency is a real risk, and how the major specialty tracks compare.
Residency Financing: Stipend-Paid, Not Tuition-Paying
| Factor | Details |
|---|---|
| PGY1 Stipend | ~$45,000–$58,000/year. Health benefits included. No tuition. Academic medical centers in high-COL areas (UCSF, UCSD affiliated programs) trend higher. |
| PGY2 Stipend | ~$48,000–$62,000/year. Same structure: employed position, benefits included, no tuition. |
| Opportunity Cost (real financial cost) | A PharmD graduate who skips residency earns ~$110,000–$130,000 from day one. Over a PGY1+PGY2 sequence, the resident earns ~$50,000–$55,000/yr instead. The gap — approximately $120,000–$150,000 in foregone earnings — is the true financial cost. The payoff is back-loaded in specialty positions and leadership tracks. |
Specialty Track Comparison
| Specialty | Job Market Risk | Notes |
|---|---|---|
| Infectious Disease | LOW — Most Promising | Antibiotic stewardship is federally mandated. Demand is broad and geographically distributed across community hospitals, academic centres, and outpatient clinics. Best combination of availability, geographic flexibility, and intellectual depth. |
| Oncology | MODERATE — Geographic Risk | Highest intellectual ceiling; excellent salaries at cancer centres. But jobs concentrate at NCI-designated and academic medical centres. Geographic inflexibility significantly raises underemployment risk. Strong fit for NPB + medicinal chemistry research profile; requires willingness to relocate. |
| Cardiology | LOW — Stable Demand | Needed at any hospital with a cardiac unit. Consistent high-volume demand across geographies. NPB cardiovascular physiology and pharmacology background is a natural fit. |
| Critical Care | LOW — Broad Availability | ICU pharmacists needed everywhere. Safest employment outlook. Trade-off: intense pace, frequent nights and weekends, notable burnout rates. |
| Ambulatory Care | LOW — Growing | Growing with value-based care and chronic disease management. More predictable hours and lifestyle than inpatient specialties. Good geographic distribution across integrated health systems, FQHCs, and large group practices. |
PGY1 graduates almost always find work. The real risk is completing both PGY1 and PGY2 — two years of stipend pay with ~$120K–$150K in foregone earnings — and ending up in a general clinical staff role that did not require either residency. This happens when graduates are geographically rigid or choose a narrow specialty with concentrated demand.
Mitigation: Choose ID, cardiology, critical care, or ambulatory care for maximum geographic flexibility, or be genuinely willing to relocate for oncology. Do not commit to a PGY2 specialty before PharmD Year 2–3; most pharmacists discover their specialty fit during clinical rotations.